Ncardia established following Pluriomics Axiogenesis merger
Builds foundation to become the trusted leader in hiPSC based drug discovery solutions.
Gosselies (BE), Cologne (DE), Leiden (NL), Philadelphia (USA), September 18th 2017 – Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The privately held company with operations in Europe and the US, produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings. [Read more…]
Pluriomics BV Partners to Offer Ultra-High Throughput Screening for Cardiovascular Drug Discovery Services
Leiden and Oss, The Netherlands, May 30th, 2017 – Pluriomics and Pivot Park Screening Centre announced a collaboration to improve Pluriomics’ cardiovascular drug discovery service offerings and to expand Pivot Park Screening Centre’s knowledge about new and innovative assay technologies used to accelerate drug discoveries. Giving Pluriomics access to the Screening Centre’s ultra High Throughput Screening (uHTS) capability, this collaboration will serve Pluriomics’ mission which is to contribute to the efficiency of the drug discovery and development process by reducing the development length, costs and late stage attrition of novel drug candidates.
Pluriomics in €2M Alliance to Develop In Vitro “Organ-on-a-Chip” Heart Failure Models
Pluriomics B.V. is a Dutch company that specializes in the “production and industrialization of high-quality, fully functional hiPS cells-derived cardiovascular cell types and on the development and realization of electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology, toxicology testing and efficacy screening.” [Read more…]
Pluriomics Awarded €3.2M to Advance Cardiovascular Drug Discovery – Reducing Time, Cost, & Late Stage Attrition of Drug Candidates
Pluriomics is a Dutch company that specializes in the “production and industrialization of high-quality, fully functional hiPS cells-derived cardiovascular cell types and on the development and realization of electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology, toxicology testing and efficacy screening.”
In news released today, the company announced that it will receive a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery.
The company also announced last month that it will lead a €2.0 million Eurostars consortium for the development of a novel in vitro organ-on-a-chip heart failure model for drug discovery and development.
To learn more about the €3.2M grant under the Horizon 2020 SME instrument programme, read the full press release below, printed with permission from Celine Hechard, PhD, VP Business Development & Marketing at Pluriomics. [Read more…]